Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation (ASAPF) generates a steady stream of news around its spinal implant platforms, biologics portfolio, and participation in medical and investor events. The company’s releases highlight developments in minimally invasive spine surgery, interventional pain management, and bone density–matched implant technology.
Recent announcements emphasize Aurora Spine’s DEXA Technology platform, including the DEXA-C cervical fusion system and the DEXA-L anterior lumbar interbody fusion device, which the company describes as bone-mimicking implants engineered to match a patient’s bone density and quality. Other news focuses on the SiLO Sacroiliac Joint Fusion System, which Aurora reports has been used in more than 2,500 procedures, and the AERO Lumbar Fusion System, a minimally invasive facet fusion device cleared for use from C2 to S1.
Investors and clinicians following ASAPF news will also see updates on Aurora Biologics, a division dedicated to allograft-based biologic solutions designed to support spinal fusion and work in concert with the company’s mechanical implants. Patent issuances, such as those covering the ZIP implant family and bone density scan–matched orthopedic implants, further illustrate Aurora’s focus on intellectual property around spinal implant design.
This news feed captures product launches, clinical usage milestones, conference participation at meetings like NASS and ASPN, and scheduled financial result releases and investor presentations. Users can monitor these updates to understand how Aurora Spine presents the evolution of its spine technologies, surgeon adoption, and broader corporate activities over time.
Aurora Spine (OTCQB: ASAPF) announced on January 8, 2026 the issuance of two independent U.S. patents that expand its implant and patient-matching technology.
The first, U.S. Patent No. 12,478,411 B2, is the tenth issued U.S. patent for the ZIP implant family and covers an implant architecture that can support motion preservation or fusion using interacting structural components to distribute load. The second, U.S. Patent No. 12,478,481 B2, protects a method for selecting implants based on bone density (DEXA) and is the company’s third patent for bone-density-matched implant systems. Both patents are now issued and enforceable in the United States.
Aurora Spine (OTCQB: ASAPF) will exhibit at the North American Spine Society (NASS) Annual Meeting from November 14–16, 2025 at the Colorado Convention Center in Denver.
Visit Booth #1622 to see live demonstrations of the newly launched Hydra facet fusion system and DEXA-L anterior lumbar interbody fusion device, part of Aurora’s patented DEXA Technology Platform that offers patient-matched implants aligned to bone density and T-Score.
Company leaders Trent Northcutt (CEO) and Laszlo Garamszegi (CTO) will highlight the products' design goals and clinical relevance for spine surgeons and attendees.
Aurora Spine (OTCQB: ASAPF) launched Aurora Biologics on Oct 27, 2025, creating a vertically integrated biologics division to pair with its interspinous, lumbar, and sacroiliac implant systems such as ZIP™, Hydra A.E.R.O.™, DEXA™, and SiLO™.
The new line includes TURBO FUSE™ Fiber Putty, OSTEO GRAFT™ DBM Putty, and OSTEO BRIDGE™ Sponge Strips, all formulated from 100% allograft bone without synthetic carriers to support osteoconduction and osteoinduction. Management said the platform is designed to improve fusion outcomes, surgical efficiency, and long-term fusion integrity and projected a more than 30% increase over prior biologic offerings.
Aurora Spine (OTCQB: ASAPF) has launched its groundbreaking DEXA-L™ Anterior Lumbar Interbody Fusion Device, marking a significant advancement in spinal surgery technology. The device is part of Aurora's patented DEXA™ Technology Platform and represents the world's first bone density matched implant for ALIF procedures.
The innovative DEXA-L™ system features bone-mimicking™ structural technology that allows surgeons to match implants to patients' specific bone density and quality. Dr. Daniel Barba of San Diego completed the first U.S. surgery using the system, highlighting its ability to expand treatment options for patients with poor bone quality. The technology addresses a significant market need, as the CDC estimates nearly 50% of Americans over 50 have low bone mass.
Aurora Spine (OTCQB: ASAPF) announced its participation in the 7th Annual ASPN Conference from July 17-20, 2025, at the Fontainebleu Miami Hotel in Miami Beach, Florida. The company will showcase at Booth 129/130 and participate in key sessions highlighting their products.
A notable highlight includes Dr. Steven Falowski's presentation of Aurora's ZIP product series, selected as one of only 12 top abstracts from 330 submissions. The presentation will discuss the REFINE Study's 12-month results on functional outcomes. Additionally, Aurora Spine will introduce their AERO Lumbar Fusion System to over 3,000 industry professionals and sponsor the ASPN Charity Reception benefiting the IRONMAN Foundation and Return to Duty.
Aurora Spine (OTCQB: ASAPF) has announced the successful completion of initial surgeries using its new AERO™ Lumbar Fusion System. The minimally invasive procedures were performed by both an orthopedic surgeon and an interventionalist on the lumbar spine region.
The AERO system, a patent-pending device cleared for use from spinal levels C2 to S1, is designed for patients with facet joint-related pain or instability. The company has 10 kits ready for future procedures and expects additional surgeons to adopt the technology in coming months. The system can be used as a standalone fusion procedure or as a complement to larger spinal fusion surgeries, targeting patients with mechanical back pain, minor instability, or degenerative joint disease who haven't responded to conservative therapies.
Aurora Spine Corporation (OTCQB: ASAPF), a leader in spine and interventional spine technology, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The company will deliver a webcast presentation at 10:15 a.m. ET and conduct one-on-one meetings with investors throughout the virtual event.
Interested parties can access the webcast through the conference homepage or directly via the provided link. The presentation will be available for replay after the event. Investors wishing to schedule one-on-one meetings with management can do so by contacting Lytham Partners or registering through the conference website.
Aurora Spine Corporation (OTCQB: ASAPF) has announced the schedule for its first quarter fiscal 2025 financial results release. The company will file results with SEDAR on Wednesday, May 21, 2025 after market hours, followed by a press release on May 22, 2025 before market trading.
A conference call for investors will be held on Thursday, May 22, 2025, at 11:00 a.m. ET / 8:00 a.m. PT. Investors can join via phone at (844) 861-5497 or (412) 317-5794, or through a live webcast. A replay will be available until May 29, 2025, and the webcast recording will be accessible for 90 days.